Literature DB >> 17407795

Sustained benefit of tadalafil in patients with pulmonary arterial hypertension with prior response to sildenafil: a case series of 12 patients.

Edgar Lik-Wui Tay, Michelle Koh Geok-Mui, Margaret Choong Poh-Hoon, James Yip.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17407795     DOI： 10.1016/j.ijcard.2007.01.046

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN： 0167-5273            Impact factor:   4.164


× No keyword cloud information.
  9 in total

1.  Safety and long-term efficacy of transition from sildenafil to tadalafil due to side effects in patients with pulmonary arterial hypertension.

Authors:  Mona Lichtblau; Dominik Harzheim; Nicola Ehlken; Alberto Marra; Fabiola Pena Pinado; Ekkehard Grünig; Benjamin Egenlauf
Journal:  Lung       Date:  2014-10-16       Impact factor: 2.584

2.  Clinical efficacy of tadalafil compared to sildenafil in treatment of moderate to severe canine pulmonary hypertension: a pilot study.

Authors:  J A Jaffey; S B Leach; L R Kong; K E Wiggen; S B Bender; C R Reinero
Journal:  J Vet Cardiol       Date:  2019-05-11       Impact factor: 1.701

3.  Non-congenital heart disease associated pediatric pulmonary arterial hypertension.

Authors:  D D Ivy; J A Feinstein; T Humpl; E B Rosenzweig
Journal:  Prog Pediatr Cardiol       Date:  2009-12-01

4.  Tadalafil: the evidence for its clinical potential in the treatment of pulmonary arterial hypertension.

Authors:  Stuart D Katz
Journal:  Core Evid       Date:  2008-07-31

Review 5.  The emergence of oral tadalafil as a once-daily treatment for pulmonary arterial hypertension.

Authors:  Jeremy A Falk; Kiran J Philip; Ernst R Schwarz
Journal:  Vasc Health Risk Manag       Date:  2010-05-06

6.  A systematic review of transition studies of pulmonary arterial hypertension specific medications.

Authors:  Avraham Sofer; Michael J Ryan; Ryan J Tedford; Joel A Wirth; Wassim H Fares
Journal:  Pulm Circ       Date:  2017-05-12       Impact factor: 3.017

7.  The Transition From Ambrisentan to Macitentan in Patients With Pulmonary Arterial Hypertension: A Real-word Prospective Study.

Authors:  Yusi Chen; Jun Luo; Jingyuan Chen; Eugene Kotlyar; Zilu Li; Wenjie Chen; Jiang Li
Journal:  Front Pharmacol       Date:  2022-01-12       Impact factor: 5.988

8.  Transition from Bosentan to Ambrisentan in Pulmonary Arterial Hypertension: A Single-Center Prospective Study.

Authors:  Jingyuan Chen; Jun Luo; Xiaojie Yang; Peng Luo; Yusi Chen; Zilu Li; Jiang Li
Journal:  Int J Gen Med       Date:  2021-05-26

Review 9.  Clinical utility of tadalafil in the treatment of pulmonary arterial hypertension: an evidence-based review.

Authors:  Adam M Henrie; James J Nawarskas; Joe R Anderson
Journal:  Core Evid       Date:  2015-11-02
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.